

AMENDMENTS TO THE CLAIMS: This listing of claims replaces all prior versions and listings of claims in the instant patent application.

What Is Claimed Is:

1. (currently amended) A composition comprising ~~[[a]] first oligomer~~ and ~~[[a]] second oligomer~~, oligomers, wherein:
 - at least a portion of said first oligomer is capable of hybridizing with at least a portion of said second oligomer,
 - at least a portion of first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and
 - at least one of said first or said second oligomers is a ~~chimeric~~ gapped oligomeric compound.
2. (original) The composition of claim 1 wherein said first and said second oligomers are a complementary pair of siRNA oligomers.
3. (original) The composition of claim 1 wherein said first and said second oligomers are an antisense/sense pair of oligomers.
4. (original) The composition of claim 1 wherein each of said first and second oligomers has 12 to 50 nucleotides.
5. (original) The composition of claim 1 wherein each of said first and second oligomers has 15 to 30 nucleotides.
6. (original) The composition of claim 1 wherein each of said first and second oligomers has 21 to 24 nucleotides.
7. (original) The composition of claim 1 wherein said first oligomer is an antisense oligomer.

8. (original) The composition of claim 7 wherein said second oligomer is a sense oligomer.
9. (original) The composition of claim 7 wherein said second oligomer has a plurality of ribose nucleotide units.
10. (currently amended) The composition of claim 1 wherein said first oligomer is a ~~chimeric~~ said gapped oligomeric compound.
- 11-12. (canceled).
14. (currently amended) The composition of claim ~~13~~ 1 wherein said ~~gapmer~~ gapped oligomeric compound comprises two terminal RNA segments having nucleotides of a first type and an internal RNA segment having nucleotides of a second type and where said nucleotides of said first type are different from said nucleotides of said second type.
15. (currently amended) The composition of claim 14 wherein each of said nucleotides of said first type independently ~~including~~ include at least one sugar ~~substituent~~; substituent selected from said sugar substituent comprising halogen, amino, trifluoroalkyl, trifluoroalkoxy, azido, aminoxy, alkyl, alkenyl, alkynyl, O-, S-, or N(R*)-alkyl; O-, S-, or N(R*)-alkenyl; O-, S- or N(R*)-alkynyl; O-, S- or N-aryl, O-, S-, or N(R*)-aralkyl;
- wherein said alkyl, alkenyl, alkynyl, aryl and aralkyl may be substituted or unsubstituted C₁ to C₁₀ alkyl, C₂ to C₁₀ alkenyl, C₂ to C₁₀ alkynyl, C₅-C₂₀ aryl or C₆-C₂₀ aralkyl; and said substituted C₁ to C₁₀ alkyl, C₂ to C₁₀ alkenyl, C₂ to C₁₀ alkynyl, C₅-C₂₀ aryl or C₆-C₂₀ aralkyl comprising substitution with alkoxy, thioalkoxy, phthalimido, halogen, amino, keto, carboxyl, nitro, nitroso, cyano, trifluoromethyl, trifluoromethoxy, imidazole, azido, hydrazino, aminoxy, isocyanato, sulfoxide, sulfone, disulfide, silyl, heterocycle, carbocycle, an intercalator, a reporter group, a conjugate, a polyamine, a polyamide, a polyalkylene glycol, or a polyether of the formula (-O-alkyl)_m, where m is 1 to about 10; and R* is hydrogen, or a protecting group.
- 16-39. (canceled)

APPLICANTS: Baker et al.
SERIAL NO: 10/701,265

DOCKET NO: ISIS-5300

40. (currently amended) The composition of claim 14 wherein said nucleotides of said first type comprise nucleotides having a 2' sugar substituent and where said 2' sugar substituent is of the formula -X-Y, wherein:

X is O, S, NR**, or CR* wherein each R** is independently H or C₁₋₆ alkyl; and

Y is substituted or unsubstituted C₁₋₂₀ alkyl, substituted or unsubstituted C₂₋₂₀ alkenyl, or substituted or unsubstituted C₆₋₂₀ aryl.

41-109. (canceled)

110. (original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

111-118. (canceled).

119. (new) The composition of claim 1 wherein each of the nucleosides in said first and second oligomers are each independently linked by a phosphodiester or a phosphorothioate internucleoside linkage.